• Publications
  • Influence
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.
Tissue factor (TF) is the primary cellular initiator of blood coagulation and a modulator of angiogenesis and metastasis in cancer. Indeed, systemic hypercoagulability in patients with cancer and TFExpand
  • 482
  • 19
  • PDF
A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles
Recently activated, but not resting, CD4+ T cells express CD154, providing costimulatory signals to B cells and antigen-presenting cells (APCs). Therefore, de novo CD154 expression after stimulationExpand
  • 268
  • 14
Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.
ErbB oncogenes drive the progression of several human cancers. Our study shows that in human carcinoma (A431) and glioma (U373) cells, the oncogenic forms of epidermal growth factor receptor (EGFR;Expand
  • 129
  • 13
  • PDF
Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression
This protocol details a method to identify CD4+ T cells that respond to antigens. The method relies on detection of CD154, a costimulatory cell surface protein that is expressed by CD4+ T cells uponExpand
  • 164
  • 12
Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry
Immune responses arise from a wide variety of cells expressing unique combinations of multiple cell-surface proteins. Detailed characterization is hampered, however, by limitations in availableExpand
  • 347
  • 8
Vaccination in Humans Generates Broad T Cell Cytokine Responses1
In recent years, the quantification of T cell responses to pathogens or immunogens has become a common tool in the evaluation of disease pathogenesis or vaccine immunogenicity. Such measurements areExpand
  • 208
  • 8
  • PDF
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Although standard anticancer chemotherapeutic drugs have been designed to inhibit the survival or growth of rapidly dividing tumor cells, it is possible to enhance the efficacy of such drugs byExpand
  • 435
  • 7
  • PDF
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
The p53 tumor suppressor gene is inactivated in the majority of human cancers. Tumor cells deficient in p53 display a diminished rate of apoptosis under hypoxic conditions, a circumstance that mightExpand
  • 442
  • 6
Shedding of tissue factor (TF)‐containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells
  • J. Yu, J. Rak
  • Medicine
  • Journal of thrombosis and haemostasis : JTH
  • 1 November 2004
909–14. 6 Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F, Musto P, Di Raimondo F, Ledda A, Lauria F, Masini L, Gobbi M, Vacca A, Ria R, Cangini D, Tura S, Baccarani M, Cavo M.Expand
  • 130
  • 4
Contrasting effects of VEGF gene disruption in embryonic stem cell‐derived versus oncogene‐induced tumors
Previous gene targeting studies have implicated an indispensable role of vascular endothelial growth factor (VEGF) in tumor angiogenesis, particularly in tumors of embryonal or endocrine origin. InExpand
  • 71
  • 4
  • PDF